Having followed the development and clinical adoption of the enVast mechanical thrombectomy device, I can share some practical insights from direct experience in the cath lab. This device has gradually gained traction due to its unique design tailored for coronary thrombus removal, especially in STEMI cases. Unlike some thrombectomy tools, enVast does not include an aspiration component, which initially raised concerns about distal embolization risks where dislodged debris might travel further downstream causing microvascular obstruction. In practice, however, the device’s mechanical action permits effective clot retrieval in many STEMI cases, demonstrated by improved angiographic results and restored blood flow. I have observed its use in multiple scenarios, including the right coronary artery (RCA), where achieving full reperfusion is critical. Operators appreciate the range of device sizes—such as 4.0 to 6.0mm diameters and varying lengths—to suit different vessel sizes and thrombus burdens. While distal embolization remains a theoretical risk, careful case selection and procedural technique mitigate this concern. Supplementing thrombectomy with PTCA often optimizes outcomes further. Moreover, enVast’s ease of deployment and mechanical thrombectomy capability make it a valuable tool in the IR lab arsenal. Sharing experiences within teams and forums helps build confidence and refine protocols. If you have tried enVast, comparing notes on clinical results and any challenges encountered would be invaluable. As the device becomes more common in hospital settings globally, real-world data will continue to guide best practices. For those working in interventional cardiology, staying informed about new thrombectomy technologies like enVast can enhance patient outcomes in acute STEMI management.